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1. Introduction  
The complex relationship of thyroid hormones (TH) with brain function is known since a 
century. The TH mediate important effects on central nervous system (CNS) during 
development and throughout life (Bauer et al., 2002a; Smith et al., 2002). Is well known that 
hyper and hypothyroidism are frequently associated with subtle behavioral and psychiatric 
symptoms. By the other side, patients with mood disorders show alterations in thyroid-
stimulating hormone (TSH) release under thyrotropin-releasing hormone (TRH) stimulation 
although, circulating TH: triiodothyronine (T3) and thyroxine (T4) are usually in the normal 
range (Linkowski et al., 1981; Loosen, 1985; Larsen et al., 2004; Risco et al., 2003). Animal 
studies have provided considerable data on the reciprocal interactions between TH and 
neurotransmitter systems related with the pathogenesis of mood disorders (Bauer et al., 
2002a). These studies provide the basis for several hypotheses, which propose that the 
modulatory effects of TH on mood are mediated by their actions on different 
neurotransmitter as norepinephrine and serotonin (Belmaker&Agam, 1998). There is also 
experimental evidence that some antidepressant drugs have some effects on brain TH 
concentration and T3 generation through a modulatory effect on deiodinases. Many trials 
have demonstrated that under certain conditions the use of TH can enhance or accelerate the 
therapeutic effects of antidepressants (Kirkegaard & Faber, 1998).  
Considering that major depression is currently viewed as a serious public health problem 
with significant social and economic consequences, we found interesting to review how 
thyroid function and brain could interact in depressive disorders and how some new 
aspects as evaluation of some polymorphism of deiodinases and neuroimaging, can help in 
identifying depressive subjects susceptible to be treat with TH. 
2. Thyroid hormones and brain 
Thyroid hormones participate in the normal neurological development increasing the rate of 
neuronal proliferation in the cerebellum, acting as the “time clock” to end neuronal 
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proliferation, differentiation and also stimulating the development of neuronal processes, 
axons and dendrites. As well TH mediate effects on CNS occur throughout life (Bauer et al., 
2002a; Smith et al., 2002). Different studies have demonstrated the presence of thyroid 
receptors in rat CNS with a particular distribution during development and adulthood 
(Bradley et al., 1992; Bradley et al., 1989). Thus, TH regulate the expression of genes 
implicated in myelination, neuronal and glial cell differentiation (Bernal, 2005; Bernal & 
Nunez, 1995) and neuronal viability and function (Smith et al., 2002). These hormones are 
able to modify cell morphology by acting on cytoskeleton machinery required for neuronal 
migration and outgrowth (Aniello et al., 1991; Morte et al., 2010). Additionally, TH are 
present in noradrenergic nuclei of CNS (Rozanov & Dratman, 1996) probably acting as 
neuromodulator or co-neurotransmitter (Dratman & Gordon, 1996). In line with this, TH 
increase ǃ-adrenergic receptors levels (Ghosh & Das, 2007; Whybrow & Prange, 1981) and 
improve both cholinergic (Smith et al., 2002) and serotonin neurotransmission in animals 
(Bauer et al., 2002a). The effect of TH on serotonin (5 HT) has been explained by a 
desensitization of 5HT1A autoreceptor in the raphe nuclei which probably results in 
enhancement of firing and release of serotonin from raphe neurons (Heal & Smith, 1988). 
Furthermore, these hormones can stimulate the expression of neuronal growth factor (NGF) 
suggesting certain trophic actions on CNS (Walker et al., 1979; Walker et al., 1981).  
In mice models, maternal hypo and hyperthyroidism cause some malformation and 
developmental defects in the cerebellar and cerebral cortex of their newborns. 
Concomitantly, there is some degeneration, deformation and severe growth retardation in 
neurons of these regions in both groups (El-Bakry et al., 2010). Therefore, TH play an 
important role in brain development, neuronal migration and axonal projection to target 
cells. In vitro and in vivo studies have shown that TH exert a non genomic action over the 
actin citoskeleton development in astrocytes and neurons. The lack of TH impaire cell 
growth, granule cells migration and explain those defects in the hypothyroid brain (Farwell 
et al., 2006; Leonard&Farwell, 1997; Farwell&Dubord, 1996). 
Moreover, both acute and chronic Thyroxine treatment in rats increases the cognitive 
function, probably through an enhancement in cholinergic neurotransmission (Smith et 
al., 2002).  
In humans, TH deficiency during the fetal and postnatal periods may cause irreversible mental 
retardation, neurological and behavioral deficits, and long lasting, irreversible motor 
dysfunctions. In adulthood, hypothyroidism may also determine profound behavioral 
consequences such as depressive symptoms, impaired memory, impairment in learning, 
verbal fluency, and spatial tasks (Miller et al., 2007; Samuels et al., 2007). Probably these 
alterations are due to neurotransmission impairment in brain areas related to learning and 
memory, such as hippocampus. Thus, the reduction of TH levels in CNS, can promote an 
altered neurotransmission activity contributing to some mood disorders like major depression. 
The biologically active thyroid hormone T3 exerts its effects by interacting with their specific 
nuclear thyroid receptors (TRs) that are positively regulated by its own ligand, acting as 
transcription factors. TRs are encoded for two different genes: TR located on chromosome 
3, encodes three isoforms: 1, 2 and 3, and TR located on chromosome 17, encodes the 
isoforms ǂ1, ǂ2 and ǂ3. TR1 is expressed early in the embryonic development and TR is 
expressed at later stages of development. By the other hand, the expression of these isoforms 
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is tissue dependent; in the brain, the main isoforms of TRs are: TRǂ1, TRǂ2, TRǃ1 and TRǃ2. 
TRǂ1 and ǂ2 accounting for most of TRs in the organ, whereas TRǃ1 and ǃ2 are detected in 
only a few areas as retina, cochlea, anterior pituitary and hypothalamus. In mice in which 
TR or TR were inactivated, different phenotypes are observed indicating that TRs 
isoforms mediate specific functions but also, they can substitute each other to mediate some 
actions of T3 (Jones et al., 2007; Forrest et al., 1996a; Forrest et al., 1996b; Wikström et al., 
1998; Fraichard et al., 1997; Göthe et al., 1999). 
Some studies have reported, in propylthiouracyl-induced hypothyroidal adult rats, a 
decreased expression of TRǂ1 and TRǃ in the hippocampus, associated with an increase in 
-amyloid peptides in the same area. Hypoactivity of the thyroid signaling in the 
hippocampus could induce modifications in the amiloydogenic pathway and this could be 
related with a greater vulnerability of developing Alzheimer disease in hypothyroidal 
subjects (Ghenimi et al., 2010). 
2.1 T3 generation in the central nervous system: The importance of deiodinases  
Although both forms of TH (T4, T3) are present in the circulating blood, some studies have 
demonstrated that T4 is transported into the brain much more efficiently than T3 (Hagen & 
Solberg, 1974). In contrast to peripheral tissue, in the brain T4 and T3 are in equimolar range 
indicating mechanisms for an efficient transformation into biological active hormone. 
TH production is regulated by the HPT axis, while its biological activity is mainly 
regulated by three selenodeiodinasas coded by different genes (D1, D2, D3). Deiodinases 
act at prereceptor level influencing both, extracellular and intracellular TH levels and its 
action. Whether it activates or inactivates it, will depend on the level where deiodination 
occurs (5 or 5` position on the iodothyronine molecule). In the periphery, in the kidney 
and liver, D1 isoform is responsible for the production of most of the circulating T3 
(Bianco et al., 2002).  
In the CNS, the most important isoforms are D2 and D3. In the brain, T3 is produced locally 
by the action of D2 which is also expressed in pituitary, thyroid, brown adipose tissue, 
skeletal muscle, and aortic smooth muscle cell, in humans. D2 activity varies extensively in 
different brain regions, with the highest levels found in cortical areas and lesser activity in 
the midbrain, pons, hypothalamus and brainstem (Bianco et al., 2002; Gouveia et al., 2005; 
Zavacki et al., 2005). It has been described in adult rats, that approximately 80% of T3 bound 
to nuclear receptors is produced locally by D2 activity (Crantz et al., 1982). Moreover, 
inactivation of TH is mainly carried out by D3 as well as glucoronosyltransferase and 
sulfotransferases. D3 is highly expressed within the CNS, with low peripheral expression. 
D3 degrades T4 to rT3 and T3 to 3,3′-diiodothyronine (T2) therefore preventing or finishing 
actions of T3. Thus,  combined actions of D2 and D3 can locally increase or decrease thyroid 
hormone signaling in a tissue -and a temporal- fashion, and more importantly in a way 
independent of thyroid hormone plasma levels. In addition, increasing evidences pointed 
out that deiodinase expression can be modulated by a wide variety of endogenous signaling 
molecules, suggesting a local modulation of T3 production in the brain (Gereben et al., 
2008a, Gereben et al., 2008b). D2 enzymatic activity is increased also in hypothyroidism and 
decreased in hyperthyroidism (Kirkegaard & Faber, 1998). 
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2.2 Association between deionidase polymorphisms and thyroid hormone 
metabolism 
Genetic variations in deionidade genes may impact significantly thyroid function and TH 
levels in euthyroid subjects (Hansen et al., 2007; Peeters et al., 2007; Peeters et al., 2006; 
Peeters et al., 2003). The effect of two polymorphisms in D1 gene, D1-rs11206244 (D1-C785T) 
and D1-rs12095080 (D1-A1814G) on thyroid hormone metabolism has been evaluated in 
randomly selected subjects (Peeters et al., 2003). The allele T of D1-rs11206244 was 
associated with high levels of rT3 and high rT3/T4 ratio and a low T3/rT3 in plasma; 
whereas the G allele of D1-A1814G was associated with a high T3/rT3 (de Jong et al., 2007; 
Peeters et al., 2003). These results suggest a lower activity in T carriers of rs11206244 than G 
carriers (Peeters et al., 2003).  
Of special interest is the common polymorphism in humans: D2 rs225014 (D2-Thr92Ala), 
characterized by a threonine (Thr) change to alanine (Ala) at codon 92 (D2 Thr92Ala). It is 
associated with insulin resistance in different populations, suggesting that D2-generated T3 in 
skeletal muscle plays a role in insulin sensitivity (Mentuccia et al., 2002, Canani et al., 2005). 
The minor allele (G) is associated with a low D2 activity in thyroid samples obtained from 
patients (Canani et al., 2005). In accordance, G allele seems to predict the need for higher T4 
intake in thyroidectomized patients (Torlontano et al., 2008).  Nonetheless, it has been 
observed that GG subjects show a delayed serum T3 rise in response to TRH-mediated TSH 
secretion consistent with decreased D2 activity (Butler et al., 2010). Some studies have 
described a naturally occurring polymorphism located in 5'-untranslated region of the D2 gene 
(Coppotelli et al., 2006). In healthy blood donors, the minor allele of this polymorphism (D2-
ORFa-Asp variant, rs12885300) is associated with an increase in circulating T3/T4 ratio but not 
with plasma T3 and TSH levels, suggesting an increased D2 gene expression (Peeters et al., 
2005). In agreement, in vitro studies suggested that D2-rs1288530 polymorphism leads to 
higher activity of D2 at the pituitary level (Coppotelli et al., 2006). In a long case-control 
Chinese study, the haplotypes ORFa-3Asp-92Ala and ORFa-3Gly-92Ala indicated higher 
susceptibility for bipolar disorders, while ORFa-3Asp-92Thr probably played a protective role 
(He et al., 2009). According to this evidence, it is feasible that variants of D2 gene can produce 
“brain hypothyroidism” limiting T3 action on CNS affecting brain neurotransmission. 
3. Thyroid and depression  
The similarity and overlapping between symptoms of depression and thyroid disorders has 
been the theoretical base for the hypothesis regarding a possible relationship between both 
entities. As we mention above, hypothyroidism could induce cognitive dysfunction and 
depressive symptoms besides psychological distress in a very similar way to primary 
depression (Constant et al., 2005; Bould et al., 2011; Mowla et al., 2011). Likewise, TH effect as 
augmentation therapy in refractory depression, and thyroid disorders as risk factors for rapid-
cycling in bipolar disorder sustain a possible association between both types of diseases. 
The involvement of HPT axis in the pathogenesis of depression is supported by multiple 
data. There are few studies that show normal range TH levels during a depressive episode; 
however most of them demonstrate diverse changes in different hormones associated with 
this axis. Concerning TSH levels, data are contradictory, some authors have reported  a 
decrease in basal TSH values as well as in those observed in response to exogenous TRH 
www.intechopen.com
 Depressive Disorders and Thyroid Function 
 
263 
(Forman-Hoffman & Philibert, 2006; Stipcević et al., 2008) and other studies showed TSH 
elevation in bipolar depression (Brouwer et al., 2005; Saxena et al., 2000).  
In reference to T3 levels, results are more conclusive, showing a trend to decrease in the 
presence of depression, as well as an association with high risk of long term relapse. In 
addition there seems to be a more pronounced T3 decrease in direct relation with the 
severity of depression (Stipcević et al, 2008; Saxena et al., 2000). Reported T4 levels in 
depression are also contradictory, since there is evidence showing a rise as well as a 
decrease of T4 during depressive episodes. (Saxena et al., 2000; Kirkegaard&Faber, 1998). In 
a study, with more than 6,000 subjects, it was shown that a low TSH and a high T4 levels 
were associated with depression specially in young men but, in women only a higher T4 
levels correlated with current depression syndrome (Forman-Hoffman&Philibert, 2006). It is 
possible that these findings could be explained by a diversity of factors, such as differences 
in phenotypes of depressive patients, severity and duration of the disease, difficulties in 
isolating drugs effects in TH levels (antidepressants and mood stabilizers) and probably, 
gender and other differences.  
Overt thyroid disease is infrequent among depressive patients. Nevertheless, many authors 
have seen that a subgroup of depressive patients manifest a subclinical hypothyroidism and 
this might be a negative prognostic factor (Fountoulakis et al., 2006). On the other side, some 
antidepressants as lithium inhibits TH secretion and could increase antithyroid antibodies, 
promoting hypothyroidism in susceptible subjects (Emerson et al., 1972; Myers et al., 1985). 
There is still no hypothesis that can satisfactory integrate these data. Interactions between 
TH and neurotransmitters, gene expression and neurohormonal receptors are not clear yet. 
For instance, 5 HT seems to inhibit TRH secretion and somatostatin TSH secretion 
(Kirkegaard&Faber, 1998); both of them are reduced in cerebro spinal fluid (CSF) in patients 
with psychiatric illness and affective disorders (Gerner&Yamada, 1982, Roy-Birne et al., 
1983; Rubinow et al., 1983). Otherwise, T3 influx to intracellular level in the brain is 
determined by many factors, including T3 and T4 circulating levels, protein transporters, 
and deiodinase activity. 
About a 25% of major depressed patients show a reduction in TSH release under TRH 
stimulation (Loosen 1985, Risco et al, 2003). It has been proposed that in them exist a 
blunted response due to the raise of circulating cortisol, associated to hypothalamic-
pituitary-adrenal axis hyperactivity. This response has also been observed in bipolar 
disorders (Linkowsky et al., 1981). On the other hand, in rapid cycling depressives, TSH 
hypersecretion is observed in response to TRH (20% of basal TSH levels above the normal 
range) (Szabadi, 1991, Larsen et al., 2004). 
Nevertheless, as we mentioned before, the mechanism by which TH affect the adult brain is 
not completely clear, because the complex interactions between neurotransmitters and 
thyroid. One hypothesis is that TH modulate the number of post-synaptic ǃ-adrenergic 
receptors in the cerebral cortex and cerebellum This could be relevant considering the 
influence of catecholamines deficit, mainly norepinephrine as a cause of depression 
(Atterwill et al., 1984). Another possible mechanism is the modulation of 5 HT and its 
receptors. It has been suggested that TH inhibit the impulse rate of neurons present at the 
raphe and reducing the release of 5HT. T3 administration to mice attenuates the function of 
5HT1A and 5HT1B receptors, increasing the cortical and hippocampus synthesis and 
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turnover of 5-HT. Administration of T3 plus electroconvulsive shock markedly potentiated 
its actions on 5-HT2-mediated responses. (Heal&Smith, 1988). These findings provide 
evidences for possible antidepressant effects of T3 and/or potentiating therapy by TH. This 
issue is relevant in patients suffering depressive disorders, related with reduction in mono 
amine neurotransmission such as serotonin (reviewed in Belmaker&Agam 2008). 
A positive correlation between serotonin levels and circulating T3 has been described in 
humans. Indirect evidences showed that brain serotonin is increased in hyperthyroidism and 
decreased in hypothyroidism (Singhal et al., 1975). In the last situation, this is reversed with 
TH replacement (Bauer et al., 2002b, Strawn et al., 2004). In depressed subjects, the decrease in 
serotoninergic tone could be related to lower brain T3 levels, perhaps due to a reduction of 
deiodinases activity. Furthermore, an imbalance in T3 conversion could account for depressive 
disorder and/or clinical outcome to antidepressants therapy. It has been suggested that in 
depression, T3 may favor the release of cortical 5-HT and thus synergize the response to 
antidepressants. Administration of desipramine a selective serotonergic reuptake inhibitor 
(SSRI) in rats, induces an increase of D2 activity and T3 concentration in cortical tissue. 
Interestingly, T4 concentrations were significantly lowered after administration of the 
antidepressant but, serum T3 levels were significantly reduced only after toxic dosis of 
desipramine. Other commonly used SSRI, fluoxetine also decreases D3 activity (Eravci et al., 
2000). Based on these data, one might suggest that depression occurs by the inhibition of D2, 
determining decreased T3 levels and secondarily, reduced levels of brain 5HT. 
The efficacy of T3 as a supplement of sertraline therapy, another SSRI, was studied recently 
in relation D1 polymorphism (Cooper-Kazaz et al., 2009). Patients carrying the T allele of 
D1-rs11206244 showed a significant response to 8 week of antidepressant treatment in 
comparison with non-carriers of the allele. Additionally, there was no effect of T allele on 
sertraline response, suggesting that the polymorphism is not associated to antidepressant 
effect (Cooper-Kazaz et al., 2009). As we mentioned, the T allele of D1-rs11206244 showed 
lower T3 and higher rT3 than non-T carriers (de Jong et al., 2007; Peeters et al., 2003). Thus, 
it seems that patients genetically characterized by poor conversion of T4 to T3, are better 
responders to T3-antidepressant co-treatment (Cooper-Kazaz et al., 2007; 2008). Another 
study evaluated whether baseline thyroid function and D2 rs225014 (D2-Thr92Ala) predict 
response to paroxetine. It showed that high TSH levels predict the response, and 
heterozygous patients showed lower TSH levels than the wild-type allele (A) (Brouwer et 
al., 2006). However, up to date there is no study evaluating the influence of T3 and D2 
polymorphisms on antidepressant response. 
Based on these observations, we evaluated the presence of D2 polymorphism related with a 
lower activity of the enzyme: D2-Thr92Ala (T/C). The polymorphism was analyzed in 61 
euthyroid patients with depression and 48 subjects of a population sample using the PCR-
RFLP method. Clinical response to fluoxetine was evaluated before and after 8 weeks of 
treatment, using Hamilton Scale for Depression (HAM-D). We found that the CC genotype 
of Thr92Ala polymorphism was more frequent in depressed subjects and in non-responders 
patients (unpublished data). We concluded that Thr92Ala polymorphism of D2 gene could 
be considered a predictive marker of clinical response to fluoxetine, and hence of 
pharmacological therapy, but more studies are needed to confirm this preliminary results.  
The presence of these polymorphisms could influence basal activity of type 2 deiodinase, 
and therefore of T3 bioavailability in the brain.  
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4. Use of thyroid hormone in depression  
Several studies using thyroid hormones in the management of patients with mood disorders 
have been reported since the early seventies. TH have been used in euthyroid depressed 
patients to enhance the effects of antidepressants. In patients receiving electroconvulsive 
therapy, those treated with T3 required less sessions and presented less memory loss 
compared with placebo treated group (Stern et al., 1991). T3 has been employed in initial 
combination therapy, and T3 or T4 in refractary depression or non responder patients. 
T3 in doses of 20 to 50 g is able to enhance the effect of tricyclic antidepressants and shorten 
the depression period but, many studies have not demonstrated differences in the number of 
patients recovered (Prange et al., 1969; Wilson et al., 1970; Coppen et al., 1972; Wheatley, 1972). 
A meta-analysis showed that when T3 was used in refractary depression in addition to 
tricyclic antidepressant therapy, patients treated with it were twice as likely to respond as 
controls, decreasing depression severity scores (Aronson et al., 1996). However, samples size 
were small and deserve more evidence. Other studies, using T3 augmentation to SSRI-resistant 
depression, observed an improvement in mood scores (Agid&Lerer, 2003, Iosifescu et al., 2005, 
Abraham et al., 2006). Some authors found that patients who responded to T3 had higher 
serum TSH levels than non-responders and T3 appears to be less effective in men than in 
women (Agid&Lerer, 2003). Other authors reported that patients with atypical depression 
experienced significantly greater clinical improvement in final HAM-D with higher rates of 
treatment response and remission compared to subjects with non-atypical major depressive 
disorder (Iosifescu et al., 2005). All those cases were treated mainly with fluoxetine in a daily 
dose of 20 to 40 mg/ and 25-50 g of T3, with few side effects.  
L-thyroxine (T4) added to antidepressants has been used less frequently than T3. Some 
authors have suggested that T4 augmentation is less effective than T3 (Joffe&Singer, 1990) 
and that supra physiological doses (250-600 ug/day) are needed, as has been demonstrated 
in patients with resistant major depression or refractary uni and bipolar disorders 
(Baumgartner et al., 1994, Bauer et al., 1998, 2002). These results support the theory of a 
reduced deiodination of T4 compatible with an inhibition of the D2 or a stimulation of the 
D3 in brain tissues resulting in reduced local T3 concentration. 
Nevertheless, the addition of T4 (100 ug /day during 4 weeks) to serotoninergic 
antidepressants obtained remission in 11 of 12 female patients with a resistant depressive 
episode but, these results did not show association with T3, T4 or TSH levels (Łojko & 
Rybakowski, 2007).  
To date, the use of TH in mood disorders is controversial and the rationale for this therapy 
is still not completely clear. Main limitations of the studies are: small number of cases, lack 
of a placebo group, heterogeneity in diagnosis criteria, differences in observational period 
and in antidepressant therapy. For example, lithium has a known inhibitory effect on TH 
secretion; fluoxetine has a stimulatory effect over D2 as well as  desipramine and both of 
them could induce deficit of T4. 
In this line, we evaluated a group of euthyroidal adult female patients with major 
depression according to DSM IV-R criteria. All of them were free of antidepressants for at 
least for 6 month. We studied the effect of adding T3 in a dose of 50 ug per day (n=11) or 
placebo (n=10), to the standard antidepressant therapy with fluoxetine during 8 weeks. At 
the end of the observational period final  HAM-D scores were similar in both groups. (See 
Table 1). Patients in T3 group showed significant T4, T3 and TSH changes; but they remain 
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clinically euthyroid during the whole treatment period. Their body mass index , heart rate 
and other clinical parameters did not change. The placebo group showed a non significant 
increase of THS at the end of the observation time (See Figure 1, unpublished results). 
 
T3 Group Placebo p 
Age (y.o.) 40±12 36±10 ns 
 
Initial 2m Initial 2m Initial vs 2m Groups 
HAM-D 24±4 8±4 26±6 7±4 <0.0001 ns 
Table 1. Age and Hamilton score (HAM-D) with 21 items, in the groups with T3 addition or 
placebo. Both initial and 2 months means±SD were similar (using non paired t student test). 
The difference between initial and 2 month was highly significant in both groups (using 
paired t tests). 
  
 
Fig. 1. TSH changes after addition of T3 or placebo in both groups. Measurements of TSH are 
shown at baseline, 1 month and 2 months using similar SSRI therapy. T3 hormone induced 
significant decreased TSH levels. No significant change was observed in placebo group. 
Summarizing, our results suggest that TH addition to SSRI therapy in euthyroid depressed 
patients is safe and has not deleterious clinical effects in spite of TSH changes during 
treatment. Although, we could not demonstrated in this particular group, a significant 
antidepressant effect. 
T3 Group Placebo 
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5. Hypothyroidism, depression and brain imaging  
Single-photon tomography (SPECT), positron emission tomography (PET) and functional 
magnetic resonance imaging (fMRI) are able to capture physiological events linked to 
underlying neuronal activity. They have been employed to image and quantify brain 
perfusion, flow and metabolism in several conditions as well as the radionuclide techniques 
have been used to map neurotransmissors, receptors, drug actions and many metabolic 
pathways. Functional imaging in mood disorders may show abnormalities at different brain 
levels that could normalize with therapy. Several serotonin and adrenergic markers have also 
been employed to study negative emotional stimuli response in mood disorders. For instance: 
thalamic activity was increased by reboxetine, whereas citalopram primarily affected 
ventrolateral prefrontal regions. It would be interesting to have a method able to predict 
therapy responses to either noradrenergic or serotoninergic antidepressants (Carey  et al., 2004; 
Navarro et al., 2004; Zobel et al., 2005; Kohn et al., 2007; MacQueen, 2009; Brühl et al., 2011). 
It is also known that even mild hypothyroidism may produce changes in brain regions 
modulating attention, motor speed, memory and visual-spatial processing. In severe 
hypothyroidism induced by thyroidectomy in cancer patients, it have been reported a clear 
parietal and partial occipital lobe hypoperfusion, measured with SPECT; the abnormalities 
improved after reaching normal thyroid function, in some subjects. However, 
fluorodeoxyglucose (FDG) and oxygen-15-labeled water studies, in similar patients, showed 
lower global brain glucose metabolism and flow. Hypothyroidal patients were also 
significantly more depressed, anxious and psychomotor slowered than euthyroidal subjects 
(Nagamachi et al., 2004; Constant et al., 2001). 
Brain metabolism and flow are usually decreased in major depression and bipolar disease 
being metabolism inversely associated with the severity of depression. Changes are variable 
and as we mentioned earlier, could reverse with adequate therapy. Subgenual prefrontal 
cortex presents abnormal blood flow and metabolism in the depressed state. Prefrontal 
cortex and limbic structures are involved in emotion regulation and amygdale is involved in 
emotional memory formation (Buchsbaum et al., 1997; Kennedy et al., 2007; Chen et al., 
2011). In major depression patients, glucose metabolism in orbitofrontal and inferior frontal 
cortex correlates with therapy response; responders have a significant decrease in the 
orbitofrontal and ventrolateral regions compared with non-responders, implicating ventral 
prefrontal subcortical circuits in response to specific therapy with SSRI. In major depression 
and bipolar patients, FDG has shown an inverse correlation between brain metabolism and 
circulating TSH (Brody et al., 1999; Marangell et al., 1997; Milak et al., 2005).  
Cerebral fMRI has been reported to be helpful in major depression intending to predict 
therapy response using brain activation. Morphometric studies have evaluated hippocampus 
volume association with response to treatment. Patients who remit have larger pretreatment 
hippocampus volumes bilaterally compared with those who do not remit. There are similar 
preliminary findings for the anterior cingulate cortex. A recent work demonstrated a 
significantly thinner posterior cingulate cortex in non-remitters than in remitters, and also 
significant decrease in perfusion in frontal lobes and anterior cingulate cortex in non-remitters 
compared with healthy controls, at baseline (MacQueen, 2009; Järnum et al., 2011).  
There are reports with increased perfusion in anterior cingulate and prefrontal medial cortex 
when using SSRI or amesergide. Responders and non-responders to cognitive behavior 
therapy versus antidepressive pharmacotherapy and deep brain stimulation could also be 
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differentiated using brain perfusion SPECT or glucose metabolism with PET (Vlassenko et 
al., 2004; Kennedy et al., 2007; Richieri et al., 2011).  
Another work with fMRI demonstrated also that successful paroxetine treatment decreases 
amygdala activation, presumably by improved frontolimbic control, in line with SSRI, 
induced increased functional connectivity between pregenual anterior cingulated cortex, 
prefrontal cortex, and amygdala. Changes in amygdala activation when processing negative 
faces expressions might serve as an indicator for improved frontolimbic control required for 
clinical response (Ruhé, 2011). 
We recently studied a group of major depression middle age patients using brain perfusion 
SPECT, all in their first episode of major depression and /or without any specific therapy 
for at least six months. Their initial HAM-D scores corresponded to 24±4.8; all of them 
received standard SSRI therapy. Ninety-three percent were responders at 2 months (HAM-D 
decrease >50%) and 59% were remitters (HAM-D score ≤5). There was association of 
decreased perfusion in diverse brain areas with HAM-D changes in the whole group using 
Statistical Parametric Analysis (SPM) as covariate (See Figure 2). We did not observe 
significant neocortical perfusion change after 2 months of standard dose of fluoxetine 
therapy. However, there was a bilateral decrease in parahippocampal gyrus, thalamus and 
striatum as well as in anterior cingulate gyrus (Brodmann 32 area) after SSRI therapy. No 
significant difference was observed between remitters and non-remitters.  
 
Fig. 2. In the whole group, SPM8 analysis demonstrated  association between decreased 
perfusion and HAM-D scores considered as a covariate, at baseline and after 2 months of 
therapy (non corrected p <0.001): -at left: in amygdala, anterior cingulate, globus pallidum, 
putamen and Brodmann area 9 (mid frontal gyrus) -bilaterally: both hyppocampal gyrus, 
mid and superior temporal and insulas and cerebellar hemispheres -at right: in central and 
supramarginal gyrus  
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As we mentioned before, a half of the women in our group received T3 in addition of SSRI and 
the other half a placebo instead of T3. Our results showed no evidence that adding T3 to SSRI 
therapy in unipolar major depression females produces significant change in regional cerebral 
blood flow at neocortical level (See Figure 3). Only a small difference was found at deep 
structure level that could imply diverse brain mechanism involved [data not published]. 
These findings are in agreement with other reports showing relative normalization of 
perfusion and metabolism that were abnormally increased at baseline in patients with mood 
disorders. Some of these regional metabolism changes are correlated with emotional 
behavior. The amygdala and limbic structures have been associated with face recognition 
and emotional processing. It is well known that there is increased perfusion and metabolism 
in specific brain areas, reflecting molecular abnormalities in neurotransmitter systems. The 
development of new molecular imaging methods could help in the individualization of 
antidepressant therapies (Chen et al., 2011). 
  
Fig. 3. Absence of regional cerebral blood flow change after SSRI therapy in T3 group, using 
Statistical Parametric Analysis (SPM8) with significant level <0.001; uncorrected p value. 
6. Conclusions 
Depressive and thyroid disorders are important public health problems. There is strong 
experimental evidence showing thyroid involvement on early stages of CNS development 
and on metabolic function of the mature brain. It is also accepted that overt hyper or 
hypothyroidism are not found frequently among  mood disorders patients except in those 
with bipolar disorders, indicating that in most cases the underlying abnormality is at 
cellular or molecular levels. Although there is a prolific literature on the relationship 
between thyroid function and depressive disorders, clear results in humans on the role of 
TH in antidepressant therapy are still lacking. There are no randomized controlled trials, 
and the number of patients included in existing studies is too small.  On the other hand, 
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more research is needed in order to define the importance of genetic variants in deiodinases 
and the role of neuroimaging into the complex interactions between HPT function and 
mood disorders and in clinical response to treatments. 
Therefore, considering the available evidence and our own experience, we can recommend 
this strategy only as an alternative treatment in major depression patients who have failed 
to respond to other measures. 
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